Targeting angiogenesis as a promising modality for the treatment of prostate cancer.
Publication/Presentation Date
11-1-2012
Abstract
Antiangiogenic therapy has been successful for the treatment of solid tumors. Several strategies have been used to target angiogenesis in prostate cancer. These strategies include blocking proangiogenic factors via monoclonal antibodies or small molecule inhibitors targeting downstream signaling effector pathways, or using agents with immune-modulatory effects. This review examines the general concepts of tumor angiogenesis and the key clinical trials that have used these agents and other novel biologics in prostate cancer. Targeting angiogenesis is still a promising treatment strategy in prostate cancer with a rational trial design and combination approach.
Volume
39
Issue
4
First Page
547
Last Page
560
ISSN
1558-318X
Published In/Presented At
Lin, J., & Kelly, W. K. (2012). Targeting angiogenesis as a promising modality for the treatment of prostate cancer. The Urologic clinics of North America, 39(4), 547–560. https://doi.org/10.1016/j.ucl.2012.07.010
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
23084530
Department(s)
Administration and Leadership
Document Type
Article